Retatrutide is an advanced investigational triple hormone receptor agonist developed for conditions linked to metabolic dysfunction, including obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). Unlike earlier incretin-based approaches, it simultaneously targets three essential pathways involved in metabolic regulation:

GLP-1 receptor: Stimulates insulin secretion, suppresses appetite, and delays gastric emptying.
GIP receptor: Enhances insulin release and may support improved fat metabolism.
Glucagon receptor: Increases energy expenditure and encourages fat breakdown through thermogenic activity.

This tri-agonist strategy delivers broader metabolic engagement than GLP-1–only or dual agonists such as semaglutide and tirzepatide. Clinical research has demonstrated notable weight reduction alongside improvements in liver fat levels and glycemic control.